

Tulissin[®]-100-

(tulathromycin injection)

Protect Your Investment



KEY FEATURE #1:

Fast-acting treatment and control of bovine respiratory disease (BRD)

ITS BENEFIT:

Goes to work in minutes to treat and control respiratory disease in high-risk cattle¹
Concentrates in the most susceptible areas of the respiratory system².

KEY FEATURE #2:

Innovative package design to prevent breakage

ITS BENEFIT:

Patented³ container design on the 250mL and 500mL bottles features an easy-grip silicone shell that offers excellent shock-absorption properties that protect against breakage. This exclusive packaging provides 92% resistance⁴ when dropped multiple times from a height of up to four feet.

KEY FEATURE #3:

Single shot convenience with 18-day pre-slaughter withdraw period

ITS BENEFIT:

Just one shot required for treatment and control. Not for use in dairy cattle 20 months of age or older, including dry cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows.

KEY FEATURE #4:

Tulissin[®] 25 (tulathromycin injection) is also available for use in non-ruminating calves

ITS BENEFIT:

Convenient dosages fit with the weights of treated animals and support judicious use of antibiotics. When using Tulissin[®] 25 injectable solution, calves intended for human consumption must not be slaughtered within 22 days from the last treatment.

IMPORTANT SAFETY INFORMATION FOR NON-RUMINATING CALVES - TULISSIN[®] 25 (tulathromycin injection):

Ensure a pre-slaughter withdrawal time of twenty-two (22) days in calves. Effects of tulathromycin on reproduction in cattle have not been determined. There may be trim loss at the injection site at slaughter. Do not use in animals known to be hypersensitive to the product.

IMPORTANT SAFETY INFORMATION FOR CATTLE - TULISSIN[®] 100 (tulathromycin injection):

Ensure a pre-slaughter withdrawal time of eighteen (18) days in cattle. Do not use in dairy cattle 20 months of age or older, including dry dairy cows. Do not use in animals known to be hypersensitive to the product.

References: ¹Villarino N, Brown SA, Martin-Jimenez T. Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. J Vet Pharmacol Ther. 2014;37(3):211-221. ²Foster DM, Martin LG, Papich MG. Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or Tulathromycin. PLoS ONE. 2016;11(2):e149100. ³Patent application n°WO2019201812 Registered international design n°DM/103483. ⁴Internal study.

sound
byte

© 2022 Virbac Corporation. All Rights Reserved. TULISSIN is a registered trademark of Virbac S.A. 02/22 13607

Tulissin[®]-100-

(tulathromycin injection)



If you trust tulathromycin, then you need
TULISSIN[®] 100 injectable solution.

Built-in Protective Shell

Patented container design on the 250mL and 500mL bottles features an easy-grip silicone shell that offers excellent shock-absorption properties that protect against breakage.



Scan the QR code to see the
shock-absorbing shell in action.

<http://vet-us.virbac.com/tulissin-100>



sound
CHECK-OFF &
ECHO NOTES **byte**

First, always ask if a Virbac representative
has been in contact recently:

**Doctor, have you recently been introduced to Tulissin[®] 100
(tulathromycin injection) Injectable Solution?**

If **YES**, confirm and discuss benefits.

If **NO**, engage/detail the customer as the primary contact.

Confidence

I believe Tulissin[®] 100
Injectable Solution will
provide an important tool for
managing Bovine Respiratory
Disease in your patients.

Neutral invitation

Let's take a look
at some basic
information about
Tulissin[®] 100
Injectable Solution...

It's the customer's decision

...so you can decide whether
Tulissin[®] 100 injectable solution
is a solution you'll consider for
your patients presenting with
signs of BRD.